Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 389
Filtrar
1.
Clin Toxicol (Phila) ; 62(9): 569-573, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39092768

RESUMEN

INTRODUCTION: In 2023, a group of experts proposed that a definition of major bleeding in pharmaceutically anticoagulated patients be used in all snakebite trials. This includes bleeding that results in death, is life-threatening, causes chronic sequelae, or consumes major healthcare resources, including bleeding into a major area or hemoglobin concentration decrease ≥20 g/L. We hypothesized that a decline in hemoglobin concentration ≥20 g/L is common but rarely clinically significant in our population of Arizona rattlesnake bite patients. METHODS: Poison center records of rattlesnake bites in humans from 2018 through 2022 were retrospectively reviewed and assessed for major bleeding by the above criteria. RESULTS: Four hundred and eighty-one patients met the inclusion criteria, of whom 265 (55.1%) had a hemoglobin concentration decrease ≥20 g/L. No patients died, and there was no evidence of bleeding into a critical organ. Three patients (1.1%) received blood transfusions. A decrease in hemoglobin concentration ≥20 g/L was 100% sensitive for identifying the major bleeding-associated outcomes; however, specificity was only 45.2%. Measures of healthcare utilization and chronic sequelae were somewhat higher in patients with a decrease in hemoglobin concentration ≥20 g/L. DISCUSSION: Laboratory manifestations of hemotoxicity were common in this population, but hemorrhage was rare. While over half of patients met the major bleeding criterion of a decline in hemoglobin concentration ≥20 g/L, only 1.1% had bleeding that was potentially life-threatening as measured by receipt of a red blood cell transfusion. None died or had bleeding into a critical area. While nonspecific for major bleeding, a drop in hemoglobin concentration correlated with worse envenomation severity: these patients received more vials of antivenom, had a higher medical bill, a longer hospital stay, and were less likely to report full recovery at 90 days. CONCLUSIONS: A decrease in hemoglobin concentration ≥20 g/L should not be used as evidence of major bleeding for Arizona rattlesnake envenomation studies, but it may have a role as an indirect marker of envenomation severity.


Asunto(s)
Crotalus , Hemorragia , Mordeduras de Serpientes , Humanos , Mordeduras de Serpientes/complicaciones , Mordeduras de Serpientes/tratamiento farmacológico , Hemorragia/inducido químicamente , Masculino , Femenino , Estudios Retrospectivos , Arizona , Persona de Mediana Edad , Adulto , Animales , Adulto Joven , Anciano , Hemoglobinas/análisis , Adolescente , Niño , Anciano de 80 o más Años , Venenos de Crotálidos/antagonistas & inhibidores , Antivenenos/uso terapéutico , Preescolar , Centros de Control de Intoxicaciones/estadística & datos numéricos
2.
Am J Emerg Med ; 84: 190.e1-190.e5, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39097519

RESUMEN

As the landscape becomes more urbanized, snakebites have increasingly become uncommon presentations to the emergency departments in Singapore, while snakebites causing significant envenomation are even rarer. In this case report, we discuss a 55-year-old man who had significant envenomation from a Shore Pit Viper (Trimeresurus Purpureomaculatus) and who was successfully treated with haemato-toxic polyvalent antivenom (HPAV). He initially presented with pain, swelling and bleeding over his wound. Due to a deterioration in his coagulation profile, he was given two doses of HPAV which is typically reserved for viperid snakes instead. Following administration of the anti-venom, the patient's coagulation profile improved, and the local soft tissue effects of the venom resolved. He did not manifest any adverse effects and was discharged uneventfully about 72 h after the snakebite. The cross-neutralization potential of HPAV for Shore Pit Viper (Trimeresurus Purpureomaculatus) venom in this case study suggests that there may be a possible common underlying chemical structure and pathophysiology among the venom proteins of various snake species. Given that Trimeresurus-specific antivenom is unavailable in most countries, this cross-neutralization strategy deserves further consideration and evaluation in similar circumstances.


Asunto(s)
Antivenenos , Venenos de Crotálidos , Mordeduras de Serpientes , Trimeresurus , Mordeduras de Serpientes/tratamiento farmacológico , Mordeduras de Serpientes/terapia , Humanos , Persona de Mediana Edad , Masculino , Antivenenos/uso terapéutico , Animales , Venenos de Crotálidos/antagonistas & inhibidores
3.
Int J Mol Sci ; 25(12)2024 Jun 07.
Artículo en Inglés | MEDLINE | ID: mdl-38928044

RESUMEN

Eastern Diamondback Rattlesnake (Crotalus adamanteus) envenomation is a medical emergency encountered in the Southeastern United States. The venom contains a snake venom thrombin-like enzyme (SVTLE) that is defibrinogenating, causing coagulopathy without effects on platelets in humans. This investigation utilized thrombelastographic methods to document this coagulopathy kinetically on the molecular level in a rabbit model of envenomation via the analyses of whole blood samples without and with platelet inhibition. Subsequently, the administration of a novel ruthenium compound containing site-directed antivenom abrogated the coagulopathic effects of envenomation in whole blood without platelet inhibition and significantly diminished loss of coagulation in platelet-inhibited samples. This investigation provides coagulation kinetic insights into the molecular interactions and results of SVTLE on fibrinogen-dependent coagulation and confirmation of the efficacy of a ruthenium antivenom. These results serve as a rationale to investigate the coagulopathic effects of other venoms with this model and assess the efficacy of this site-directed antivenom.


Asunto(s)
Antivenenos , Coagulación Sanguínea , Venenos de Crotálidos , Crotalus , Animales , Conejos , Antivenenos/farmacología , Venenos de Crotálidos/farmacología , Venenos de Crotálidos/antagonistas & inhibidores , Coagulación Sanguínea/efectos de los fármacos , Tromboelastografía , Rutenio/química , Rutenio/farmacología , Mordeduras de Serpientes/tratamiento farmacológico , Masculino , Serpientes Venenosas
4.
Int J Mol Sci ; 25(12)2024 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-38928132

RESUMEN

Ruthenium chloride (RuCl3) is widely utilized for synthesis and catalysis of numerous compounds in academia and industry and is utilized as a key molecule in a variety of compounds with medical applications. Interestingly, RuCl3 has been demonstrated to modulate human plasmatic coagulation and serves as a constituent of a compounded inorganic antivenom that neutralizes the coagulopathic effects of snake venom in vitro and in vivo. Using thrombelastography, this investigation sought to determine if RuCl3 inhibition of the fibrinogenolytic effects of Crotalus atrox venom could be modulated by vehicle composition in human plasma. Venom was exposed to RuCl3 in 0.9% NaCl, phosphate-buffered saline (PBS), or 0.9% NaCl containing 1% dimethyl sulfoxide (DMSO). RuCl3 inhibited venom-mediated delay in the onset of thrombus formation, decreased clot growth velocity, and decreased clot strength. PBS and DMSO enhanced the effects of RuCl3. It is concluded that while a Ru-based cation is responsible for significant inhibition of venom activity, a combination of Ru-based ions containing phosphate and DMSO enhances RuCl3-mediated venom inhibition. Additional investigation is indicated to determine what specific Ru-containing molecules cause venom inhibition and what other combinations of inorganic/organic compounds may enhance the antivenom effects of RuCl3.


Asunto(s)
Antivenenos , Coagulación Sanguínea , Venenos de Crotálidos , Crotalus , Dimetilsulfóxido , Humanos , Dimetilsulfóxido/farmacología , Dimetilsulfóxido/química , Antivenenos/farmacología , Antivenenos/química , Venenos de Crotálidos/antagonistas & inhibidores , Venenos de Crotálidos/farmacología , Animales , Coagulación Sanguínea/efectos de los fármacos , Compuestos de Rutenio/farmacología , Compuestos de Rutenio/química , Cloruro de Sodio/farmacología , Cloruro de Sodio/química , Tromboelastografía , Serpientes Venenosas
5.
Int J Mol Sci ; 25(10)2024 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-38791221

RESUMEN

Snakebite accidents, neglected tropical diseases per the WHO, pose a significant public health threat due to their severity and frequency. Envenomation by Bothrops genus snakes leads to severe manifestations due to proteolytic enzymes. While the antibothropic serum produced by the Butantan Institute saves lives, its efficacy is limited as it fails to neutralize certain serine proteases. Hence, developing new-generation antivenoms, like monoclonal antibodies, is crucial. This study aimed to explore the inhibitory potential of synthetic peptides homologous to the CDR3 regions of a monoclonal antibody targeting a snake venom thrombin-like enzyme (SVTLE) from B. atrox venom. Five synthetic peptides were studied, all stable against hydrolysis by venoms and serine proteases. Impressively, four peptides demonstrated uncompetitive SVTLE inhibition, with Ki values ranging from 10-6 to 10-7 M. These findings underscore the potential of short peptides homologous to CDR3 regions in blocking snake venom toxins, suggesting their promise as the basis for new-generation antivenoms. Thus, this study offers potential advancements in combatting snakebites, addressing a critical public health challenge in tropical and subtropical regions.


Asunto(s)
Anticuerpos Monoclonales , Bothrops , Péptidos , Serina Proteasas , Animales , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/farmacología , Péptidos/química , Péptidos/farmacología , Serina Proteasas/química , Serina Proteasas/metabolismo , Antivenenos/química , Antivenenos/inmunología , Antivenenos/farmacología , Regiones Determinantes de Complementariedad/química , Venenos de Crotálidos/antagonistas & inhibidores , Venenos de Crotálidos/inmunología , Venenos de Crotálidos/enzimología , Venenos de Crotálidos/química , Secuencia de Aminoácidos , Inhibidores de Serina Proteinasa/química , Inhibidores de Serina Proteinasa/farmacología
6.
Clin Toxicol (Phila) ; 62(5): 314-321, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38804837

RESUMEN

INTRODUCTION: North American pit viper envenomation occurs over 4,000 times annually in the United States, with polyvalent Fab antivenom being the primary treatment. Fasciotomy is occasionally performed due to concerns about compartment syndrome. We utilized our direct access to Texas Poison Center Network data to create a new snakebite abstraction form and database on relevant available information between 2004 and 2021 and to identify, describe, and estimate the incidence of fasciotomy following pit viper envenomation in Texas. METHODS: We searched the Texas Poison Center Network database for cases during 2004-2021 using keywords such as fasciotomy, surgery, compartment pressure, and compartment syndrome. Descriptive statistics summarized the data. RESULTS: Of 16,911 reported envenomations, 0.69 percent involved fasciotomies (n = 117). Most common bite sites were digits/hands and lower extremities. Patients who underwent fasciotomy were typically male, aged 20-59, and 10 years younger than the total snakebite population. Only 6 percent of reported compartment syndrome cases had a compartment pressure measurement. Antivenom was administered in 101 (86.3 percent) cases, 92 (91.1 percent) of which received only Fab antivenom product. Patients with bites from rattlesnakes (47.9 percent) were associated with most fasciotomies. DISCUSSION: Our findings suggest a potential increase in snakebite exposures, accompanied by a decrease in fasciotomies. Overall, copperheads constituted the majority of snakebites, but most fasciotomies were from rattlesnake envenomations (47.9 percent). In this cohort, compartment syndrome diagnosis and decisions regarding fasciotomy were primarily based on clinical evaluation/surgeon expertise without compartment pressure measurements. Despite the efficacy of antivenom, only 86.3 percent of patients in our study received antivenom. CONCLUSIONS: Fasciotomy after North American pit viper envenomation in Texas is uncommon (0.69 percent) and has decreased over time, possibly due to increased antivenom use or surgeon comfort with nonsurgical management.


Asunto(s)
Antivenenos , Síndromes Compartimentales , Fasciotomía , Mordeduras de Serpientes , Mordeduras de Serpientes/epidemiología , Texas/epidemiología , Humanos , Antivenenos/uso terapéutico , Masculino , Adulto , Animales , Femenino , Persona de Mediana Edad , Síndromes Compartimentales/etiología , Síndromes Compartimentales/epidemiología , Síndromes Compartimentales/cirugía , Adulto Joven , Niño , Adolescente , Crotalinae , Preescolar , Anciano , Centros de Control de Intoxicaciones/estadística & datos numéricos , Venenos de Crotálidos/antagonistas & inhibidores , Bases de Datos Factuales
7.
Toxicon ; 242: 107711, 2024 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-38583578

RESUMEN

Crotalus neutralizing factor (CNF) is an endogenous glycoprotein from Crotalus durissus terrificus snake blood that inhibits secretory phospholipases A2 (sPLA2) from the Viperid but not from Elapid venoms (subgroups IA and IIA, respectively). In the present study, we demonstrated that CNF can inhibit group III-PLA2 from bee venom by forming a stable enzyme-inhibitor complex. This finding opens up new possibilities for the potential use of CNF and/or CNF-based derivatives in the therapeutics of bee stings.


Asunto(s)
Venenos de Abeja , Crotalus , Serpientes Venenosas , Animales , Venenos de Abeja/farmacología , Inhibidores de Fosfolipasa A2/farmacología , Venenos de Crotálidos/antagonistas & inhibidores , Abejas , Fosfolipasas A2 , Glicoproteínas/farmacología , Fosfolipasas A2 Secretoras/antagonistas & inhibidores
8.
Bol. latinoam. Caribe plantas med. aromát ; 23(2): 199-213, mar. 2024. graf
Artículo en Inglés | LILACS | ID: biblio-1552114

RESUMEN

To study the effect of 50% ethanol extract of Bougainvillea xbuttiana on the enzymatic activity, cell via bility and cytokine production provoked by the venom of Bothrops jararaca in macro - phages. Three assays were used to study the effects of B. xbuttiana extract on the damage pro - duced by B. jararaca : Enzymatic activity was detected by measuring the proteoly tic and phos - pholipase A2; macrophages cytotoxicity was determined by the MTT method; levels of cytokine were evaluated using ELISA and a biological assay. After treatment with 300 µg/mL B. xbuttiana extract for 30 min, the proteolytic and phospholipase A2 activities of the venom were reduced to 95 and 61%, respectively. In macrophages cultures treated with B. xbuttiana extract combined with venom, the production of TNF - α, IL - 6 and IFN - γ was reduced, whereas IL - 10 was potenti - ated. Our results support the potential effect of the B. xbuttiana extract as a complementary therapy against the toxicity caused by the venom of B . jararaca snakes


Estudiar el efecto del extracto etanólico al 50% de Bougainvillea xbuttiana sobre la actividad enzimática viabilidad celular y producci ón de citoquinas provocada por el veneno de Bothrops jararaca en macrófagos Se utilizaron tres ensayos para estudiar los efectos del extracto de B. xbuttiana sobre el daño producido por B. jararaca : Se detectó actividad enzimática mediante la medición del proteolítico y fosfolipasa A2; la citotoxicidad de los macrófagos se determinó por el método MTT; Los niveles de citoquinas se evaluaron utilizando ELISA y un ensayo biológico. Después del tratamiento con 300 µg/mL de extracto de B. xbuttiana durante 30 mi n, las actividades proteolíticas y de fosfolipasa A2 del veneno se redujeron a 95 y 61%, respectivamente. En cultivos de macrófagos tratados con extracto de B. xbuttiana combinado con veneno, la producción de TNF - α, IL - 6 e IFN - γ se redujeron, mientras que IL - 10 se potenció. Nuestros resultados apoyan el efecto potencial del extracto de B. xbuttiana como terapia complementaria frente a la toxicidad provocada por el veneno de B. jararaca .


Asunto(s)
Animales , Femenino , Ratones , Extractos Vegetales/farmacología , Venenos de Crotálidos/antagonistas & inhibidores , Nyctaginaceae/química , Ensayo de Inmunoadsorción Enzimática , Supervivencia Celular/efectos de los fármacos , Citocinas , Venenos de Crotálidos/enzimología , Etanol , Fosfolipasas A2 , Macrófagos/efectos de los fármacos , Ratones Endogámicos BALB C
10.
J Ethnopharmacol ; 283: 114710, 2022 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-34626780

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Snakebite envenoming is a public health problem of high impact in Central America. Bothrops asper, known as barba amarilla, terciopelo, and equis, is the snake species responsible for most snakebites in Central America. In this region, there is a long-standing tradition on the use of plants in the management of snakebites, especially in indigenous communities. Ethnomedical use of Eryngium foetidum L., Neurolaena lobata (L.) Cass. and Pimenta dioica (L.) Merr. to treat snakebite envenoming has been reported in Belice, Guatemala, Nicaragua, and Costa Rica. Extracts of the leaves of these plants have shown anti-venom activities in in vitro assays in previous studies. AIM OF THE STUDY: To assess the ability of organic fractions from these three plants to inhibit enzymatic activities associated with toxicity of the venom of B. asper, and to study, by docking analysis, the interaction of metalloproteinase and phospholipases A2 (PLA2) from B. asper venom with secondary metabolites previously described in these plants. MATERIALS AND METHODS: Organic fractions were obtained from these three plant species and their ability to neutralize proteolytic, PLA2 and in vitro coagulant activities of B. asper venom was assessed. A phytochemical analysis was carried out in these fractions. The interaction of secondary metabolites previously described in these plants with three toxins from B. asper venom (a metalloproteinase, a PLA2 and a PLA2 homologue) was investigated by docking analysis. RESULTS: The inhibitory activity of plants was mainly concentrated in their polar fractions. Acetonic fraction from P. dioica was the most active against PLA2 activity, while the acetonic fraction of E. foetidum completely inhibited the proteolytic activity of the venom. Coagulant activity was partially inhibited only by the acetone and ethyl acetate fractions of P. dioica. Phytochemical analysis of the most bioactive fractions identified flavonoids, saponins, essential oils, coumarins, alkaloids, tannins and sesquiterpene lactones. Docking analysis revealed high affinity interactions of several secondary metabolites of these plants with residues in the vicinity of the catalytic site of these enzymes and, in the case of PLA2 homologue myotoxin II, in the hydrophobic channel. CONCLUSIONS: Various fractions from these plants have inhibitory activity against enzymatic actions of B. asper venom which are directly associated with toxicological effects. Docking analysis showed structural evidence of the interaction of secondary metabolites with three toxins. These observations provide support to the potential of these plants to inhibit relevant toxic components of this snake venom.


Asunto(s)
Antivenenos/farmacología , Venenos de Crotálidos/antagonistas & inhibidores , Extractos Vegetales/farmacología , Mordeduras de Serpientes/tratamiento farmacológico , Animales , Antivenenos/aislamiento & purificación , Asteraceae/química , Bothrops , América Central , Eryngium/química , Humanos , Medicina Tradicional , Simulación del Acoplamiento Molecular , Fitoquímicos/química , Fitoquímicos/aislamiento & purificación , Fitoquímicos/farmacología , Pimenta/química , Hojas de la Planta
11.
Cienc. tecnol. salud ; 9(2)2022. il 27
Artículo en Inglés | LILACS, DIGIUSAC, LIGCSA | ID: biblio-1416719

RESUMEN

There are few scientific studies that explore the use of medicinal plants for snakebite envenoming in Central America, although plant-based therapies have been traditionally used in the region. This work reviews the studies conducted in Central America to assess the ability of extracts obtained from plants of local ethnomedical use to inhibit toxic activities of the venom of Bothrops asper, the snake responsible for approximately half of the snakebite envenomings in these countries. The search prioritized the description of the plants used in Guatemala, since most of the studies described in this work were conducted in that country, although references to other countries are included. Information concerning secondary metabolites and other pharmacological activities of these plant species, relevant to the treatment of snakebites, was also described. The literature search was conducted in the Google Scholar, PubMed and Scopus databases and completed with locally available literature. It was found that extracts of 12 plant species inhibited the hemorrhagic effect of the venom and three neutralized the edema-forming activity, while inhibition of proteolytic and phospholipase A2 (PLA2) activities was achieved by three and one plant species, respectively. Only Brownea rosa-de-monte was able to effectively counteract the in vitro coagulant effect of the venom. Some plant extracts screened in Guatemala demonstrated procoagulant or anti-thrombin intrinsic effects that might aggravate the coagulopathy induced by the venom. These findings underscore the need of carrying out scientific studies aimed to validate the inhibitory potential of Central American plant extracts and their metabolites against B. asper venom.


Pocos estudios científicos han explorado el uso de plantas medicinales para el tratamiento del envenenamiento ofídico en Centroamérica, a pesar de que las terapias basadas en plantas son de uso tradicional en la región. Este trabajo recopiló información sobre los estudios realizados en Centroamérica para evaluar la capacidad de extractos de plantas de uso etno-médico para inhibir las actividades tóxicas del veneno de Bothrops asper, la serpiente responsable de aproximadamente la mitad de los envenenamientos ofídicos en Centroamérica. La búsqueda priorizó la descripción de plantas utilizadas en Gua-temala, ya que la mayoría de los estudios aquí descritos fueron realizados en ese país. También se incluyó la descripción de los metabolitos secundarios y otras actividades farmacológicas de las especies evaluadas, que podrían explicar su uso como antiofídicos. La búsqueda de literatura se realizó en las bases de datos de Google Scholar, PubMed, Scopus, y se completó con literatura disponible localmente. Se determinó que 12 extractos de plantas inhibieron el efecto hemorrágico del veneno y tres el efecto edematígeno; la actividad proteolítica fue inhibida por extractos de tres especies y la fosfolipasa A2 (PLA2) por una especie. Solamente Brownea rosa-de-monte demostró inhibir efectivamente el efecto coagulante del veneno in vitro. Algunos extractos de las plantas tamizadas en Guatemala demostraron efectos procoagulantes o anti-trombina intrínsecos, que podrían agravar las alteraciones inducidas por el veneno en la coagulación. Estos hallazgos enfatizan la necesidad de validar el potencial de extractos de plantas centroamericanas y sus metabolitos secundarios para neutralizar el veneno de B. asper.


Asunto(s)
Humanos , Animales , Plantas Medicinales/efectos de los fármacos , Antivenenos/farmacología , Extractos Vegetales/farmacología , Bothrops , Venenos de Crotálidos/antagonistas & inhibidores , Mordeduras de Serpientes/tratamiento farmacológico , Coagulación Sanguínea/efectos de los fármacos , Antivenenos/uso terapéutico , Guatemala
12.
Toxins (Basel) ; 13(11)2021 11 13.
Artículo en Inglés | MEDLINE | ID: mdl-34822585

RESUMEN

In the Brazilian Amazon, Bothrops atrox snakebites are frequent, and patients develop tissue damage with blisters sometimes observed in the proximity of the wound. Antivenoms do not seem to impact blister formation, raising questions regarding the mechanisms underlying blister formation. Here, we launched a clinical and laboratory-based study including five patients who followed and were treated by the standard clinical protocols. Blister fluids were collected for proteomic analyses and molecular assessment of the presence of venom and antivenom. Although this was a small patient sample, there appeared to be a correlation between the time of blister appearance (shorter) and the amount of venom present in the serum (higher). Of particular interest was the biochemical identification of both venom and antivenom in all blister fluids. From the proteomic analysis of the blister fluids, all were observed to be a rich source of damage-associated molecular patterns (DAMPs), immunomodulators, and matrix metalloproteinase-9 (MMP-9), suggesting that the mechanisms by which blisters are formed includes the toxins very early in envenomation and continue even after antivenom treatment, due to the pro-inflammatory molecules generated by the toxins in the first moments after envenomings, indicating the need for local treatments with anti-inflammatory drugs plus toxin inhibitors to prevent the severity of the wounds.


Asunto(s)
Antivenenos/administración & dosificación , Vesícula/metabolismo , Venenos de Crotálidos/toxicidad , Mordeduras de Serpientes/complicaciones , Animales , Antivenenos/metabolismo , Bothrops , Brasil , Venenos de Crotálidos/antagonistas & inhibidores , Femenino , Humanos , Masculino , Proteómica , Mordeduras de Serpientes/terapia
13.
Int J Mol Sci ; 22(17)2021 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-34502548

RESUMEN

Toxins from Bothrops venoms targeting hemostasis are responsible for a broad range of clinical and biological syndromes including local and systemic bleeding, incoagulability, thrombotic microangiopathy and macrothrombosis. Beyond hemostais disorders, toxins are also involved in the pathogenesis of edema and in most complications such as hypovolemia, cardiovascular collapse, acute kidney injury, myonecrosis, compartmental syndrome and superinfection. These toxins can be classified as enzymatic proteins (snake venom metalloproteinases, snake venom serine proteases, phospholipases A2 and L-amino acid oxidases) and non-enzymatic proteins (desintegrins and C-type lectin proteins). Bleeding is due to a multifocal toxicity targeting vessels, platelets and coagulation factors. Vessel damage due to the degradation of basement membrane and the subsequent disruption of endothelial cell integrity under hydrostatic pressure and tangential shear stress is primarily responsible for bleeding. Hemorrhage is promoted by thrombocytopenia, platelet hypoaggregation, consumption coagulopathy and fibrin(ogen)olysis. Onset of thrombotic microangiopathy is probably due to the switch of endothelium to a prothrombotic phenotype with overexpression of tissue factor and other pro-aggregating biomarkers in association with activation of platelets and coagulation. Thrombosis involving large-caliber vessels in B. lanceolatus envenomation remains a unique entity, which exact pathophysiology remains poorly understood.


Asunto(s)
Trastornos de la Coagulación Sanguínea/fisiopatología , Venenos de Crotálidos/metabolismo , Hemorragia/fisiopatología , Hemostasis/fisiología , Trombosis/fisiopatología , Animales , Antivenenos/uso terapéutico , Coagulación Sanguínea/efectos de los fármacos , Coagulación Sanguínea/fisiología , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Plaquetas/efectos de los fármacos , Plaquetas/fisiología , Venenos de Crotálidos/antagonistas & inhibidores , Humanos
14.
Toxins (Basel) ; 13(4)2021 03 31.
Artículo en Inglés | MEDLINE | ID: mdl-33807363

RESUMEN

Snake envenomation can result in hemorrhage, local necrosis, swelling, and if not treated properly can lead to adverse systemic effects such as coagulopathy, nephrotoxicity, neurotoxicity, and cardiotoxicity, which can result in death. As such, snake venom metalloproteinases (SVMPs) and disintegrins are two toxic components that contribute to hemorrhage and interfere with the hemostatic system. Administration of a commercial antivenom is the common antidote to treat snake envenomation, but the high-cost, lack of efficacy, side effects, and limited availability, necessitates the development of new strategies and approaches for therapeutic treatments. Herein, we describe the neutralization ability of anti-disintegrin polyclonal antibody on the activities of isolated disintegrins, P-II/P-III SVMPs, and crude venoms. Our results show disintegrin activity on platelet aggregation in whole blood and the migration of the SK-Mel-28 cells that can be neutralized with anti-disintegrin polyclonal antibody. We characterized a SVMP and found that anti-disintegrin was also able to inhibit its activity in an in vitro proteolytic assay. Moreover, we found that anti-disintegrin could neutralize the proteolytic and hemorrhagic activities from crude Crotalus atrox venom. Our results suggest that anti-disintegrin polyclonal antibodies have the potential for a targeted approach to neutralize SVMPs in the treatment of snakebite envenomations.


Asunto(s)
Anticuerpos Neutralizantes/farmacología , Antivenenos/farmacología , Venenos de Crotálidos/antagonistas & inhibidores , Crotalus , Desintegrinas/antagonistas & inhibidores , Metaloproteasas/antagonistas & inhibidores , Inhibidores de Proteasas/farmacología , Mordeduras de Serpientes/tratamiento farmacológico , Regulación Alostérica , Animales , Especificidad de Anticuerpos , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Reacciones Cruzadas , Venenos de Crotálidos/enzimología , Venenos de Crotálidos/inmunología , Modelos Animales de Enfermedad , Desintegrinas/inmunología , Desintegrinas/metabolismo , Hemorragia/enzimología , Hemorragia/etiología , Hemorragia/prevención & control , Humanos , Metaloproteasas/inmunología , Metaloproteasas/metabolismo , Ratones Endogámicos BALB C , Agregación Plaquetaria/efectos de los fármacos , Mordeduras de Serpientes/sangre , Mordeduras de Serpientes/enzimología , Mordeduras de Serpientes/inmunología
15.
Front Immunol ; 12: 628113, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33790901

RESUMEN

Background: The immunologic pathways activated during snakebite envenoming (SBE) are poorly described, and their association with recovery is unclear. The immunologic response in SBE could inform a prognostic model to predict recovery. The purpose of this study was to develop pre- and post-antivenom prognostic models comprised of clinical features and immunologic cytokine data that are associated with recovery from SBE. Materials and Methods: We performed a prospective cohort study in an academic medical center emergency department. We enrolled consecutive patients with Crotalinae SBE and obtained serum samples based on previously described criteria for the Surgical Critical Care Initiative (SC2i)(ClinicalTrials.gov Identifier: NCT02182180). We assessed a standard set of clinical variables and measured 35 unique cytokines using Luminex Cytokine 35-Plex Human Panel pre- and post-antivenom administration. The Patient-Specific Functional Scale (PSFS), a well-validated patient-reported outcome of functional recovery, was assessed at 0, 7, 14, 21 and 28 days and the area under the patient curve (PSFS AUPC) determined. We performed Bayesian Belief Network (BBN) modeling to represent relationships with a diagram composed of nodes and arcs. Each node represents a cytokine or clinical feature and each arc represents a joint-probability distribution (JPD). Results: Twenty-eight SBE patients were enrolled. Preliminary results from 24 patients with clinical data, 9 patients with pre-antivenom and 11 patients with post-antivenom cytokine data are presented. The group was mostly female (82%) with a mean age of 38.1 (SD ± 9.8) years. In the pre-antivenom model, the variables most closely associated with the PSFS AUPC are predominantly clinical features. In the post-antivenom model, cytokines are more fully incorporated into the model. The variables most closely associated with the PSFS AUPC are age, antihistamines, white blood cell count (WBC), HGF, CCL5 and VEGF. The most influential variables are age, antihistamines and EGF. Both the pre- and post-antivenom models perform well with AUCs of 0.87 and 0.90 respectively. Discussion: Pre- and post-antivenom networks of cytokines and clinical features were associated with functional recovery measured by the PSFS AUPC over 28 days. With additional data, we can identify prognostic models using immunologic and clinical variables to predict recovery from SBE.


Asunto(s)
Venenos de Crotálidos/inmunología , Crotalinae/inmunología , Citocinas/sangre , Mordeduras de Serpientes/inmunología , Adulto , Anciano , Animales , Antivenenos/uso terapéutico , Biomarcadores/sangre , Venenos de Crotálidos/antagonistas & inhibidores , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos Inmunológicos , Valor Predictivo de las Pruebas , Estudios Prospectivos , Recuperación de la Función , Mordeduras de Serpientes/sangre , Mordeduras de Serpientes/tratamiento farmacológico , Factores de Tiempo , Resultado del Tratamiento
16.
Artículo en Inglés | MEDLINE | ID: mdl-33676005

RESUMEN

We investigated the antiophidic properties of isohemigossypolone (ISO), a naphthoquinone isolated from the outer bark of the Pachira aquatic Aubl. The inhibition of phospholipase A2, coagulant, fibrinogenolytic, hemorrhagic and myotoxic activities induced by Bothrops pauloensis venom (Pb) was investigated. For this, we use samples resulting from the incubation of Pb with ISO in different concentrations (1:1, 1:5 and 1:10 w/w), we also evaluated the condition of treatment using ISO after 15 min of venom inoculation. The activities of phospholipase A2, coagulant, fibrinogenolytic, hemorrhagic and myotoxic induced by the B. pauloensis venom were significantly inhibited when the ISO was pre-incubated with the crude venom. For in vivo neutralization tests, the results were observed even when the ISO was applied after 15 min of inoculation of the venom or metalloprotease (BthMP). Also, to identify the inhibition mechanism, we performed in silico assays, across simulations of molecular coupling and molecular dynamics, it was possible to identify the modes of interaction between ISO and bothropic toxins BmooMPα-I, Jararacussin-I and BNSP-7. The present study shows that naphthoquinone isohemigossypolone isolated from the P. aquatica plant inhibited part of the local and systemic damage caused by venom proteins, demonstrating the pharmacological potential of this compound in neutralizing the harmful effects caused by snakebites.


Asunto(s)
Bombacaceae/química , Venenos de Crotálidos/antagonistas & inhibidores , Naftoquinonas , Extractos Vegetales , Mordeduras de Serpientes/tratamiento farmacológico , Animales , Masculino , Metaloproteasas/metabolismo , Ratones , Naftoquinonas/química , Naftoquinonas/farmacología , Fosfolipasas A2/metabolismo , Corteza de la Planta/química , Extractos Vegetales/farmacología
17.
Clin Toxicol (Phila) ; 59(11): 1023-1026, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33703984

RESUMEN

INTRODUCTION: Anavip (F(ab')2AV) is a lyophilized F(ab')2 immunoglobulin fragment derived from horses immunized with venom from Bothrops asper and Crotalus durissus. It was approved by the FDA in 2015 for treatment of North American rattlesnake envenomation but not for Agkistrodon envenomation. Published data regarding the efficacy and safety of Anavip in treating Agkistrodon envenomations is limited. We present a case of a patient treated with Anavip after confirmed Agkistrodon laticinctus envenomation. CASE DETAILS: A 77 year-old man was bitten on his fifth finger by a captive A. laticinctus. He was taken to a local emergency department where he received a 10 vial initial dose of F(ab')2AV for pain and swelling and was transferred. At the receiving facility, his pain had improved and his swelling had not progressed. Over the next 30 h, his platelets declined to 132,000/mm3 and he received an additional 4 vials of F(ab')2AV. The remainder of his course was unremarkable with complete recovery by 3 months. DISCUSSION: This case provides an additional published datapoint on the use of this F(ab')2AV in the treatment of envenomation by Agkistrodon.


Asunto(s)
Agkistrodon , Antivenenos/uso terapéutico , Venenos de Crotálidos/antagonistas & inhibidores , Fragmentos Fab de Inmunoglobulinas/uso terapéutico , Mordeduras de Serpientes/tratamiento farmacológico , Anciano , Agkistrodon/metabolismo , Animales , Antivenenos/efectos adversos , Venenos de Crotálidos/metabolismo , Humanos , Fragmentos Fab de Inmunoglobulinas/efectos adversos , Masculino , Mordeduras de Serpientes/diagnóstico , Mordeduras de Serpientes/metabolismo , Resultado del Tratamiento
18.
Toxins (Basel) ; 13(2)2021 01 22.
Artículo en Inglés | MEDLINE | ID: mdl-33499001

RESUMEN

The toxin composition of snake venoms and, thus, their functional activity, can vary between and within species. Intraspecific venom variation across a species' geographic range is a major concern for antivenom treatment of envenomations, particularly for countries like French Guiana that lack a locally produced antivenom. Bothrops asper and Bothrops atrox are the most medically significant species of snakes in Latin America, both producing a variety of clinical manifestations, including systemic bleeding. These pathophysiological actions are due to the activation by the venom of the blood clotting factors Factor X and prothrombin, thereby causing severe consumptive coagulopathy. Both species are extremely wide-ranging, and previous studies have shown their venoms to exhibit regional venom variation. In this study, we investigate the differential coagulotoxic effects on human plasma of six venoms (four B. asper and two B. atrox samples) from different geographic locations, spanning from Mexico to Peru. We assessed how the venom variation of these venom samples affects neutralisation by five regionally available antivenoms: Antivipmyn, Antivipmyn-Tri, PoliVal-ICP, Bothrofav, and Soro Antibotrópico (SAB). The results revealed both inter- and intraspecific variations in the clotting activity of the venoms. These variations in turn resulted in significant variation in antivenom efficacy against the coagulotoxic effects of these venoms. Due to variations in the venoms used in the antivenom production process, antivenoms differed in their species-specific or geographical neutralisation capacity. Some antivenoms (PoliVal-ICP, Bothrofav, and SAB) showed species-specific patterns of neutralisation, while another antivenom (Antivipmyn) showed geographic-specific patterns of neutralisation. This study adds to current knowledge of Bothrops venoms and also illustrates the importance of considering evolutionary biology when developing antivenoms. Therefore, these results have tangible, real-world implications by aiding evidence-based design of antivenoms for treatment of the envenomed patient. We stress that these in vitro studies must be backed by future in vivo studies and clinical trials before therapeutic guidelines are issued regarding specific antivenom use in a clinical setting.


Asunto(s)
Anticuerpos Neutralizantes/farmacología , Antivenenos/farmacología , Coagulación Sanguínea/efectos de los fármacos , Bothrops , Venenos de Crotálidos/antagonistas & inhibidores , Hemorragia/tratamiento farmacológico , Mordeduras de Serpientes/tratamiento farmacológico , Animales , Especificidad de Anticuerpos , Bothrops/inmunología , Bothrops/metabolismo , Reacciones Cruzadas , Venenos de Crotálidos/inmunología , Venenos de Crotálidos/metabolismo , Hemorragia/sangre , Hemorragia/inmunología , Humanos , Mordeduras de Serpientes/sangre , Mordeduras de Serpientes/inmunología , Especificidad de la Especie
19.
J Med Toxicol ; 17(1): 48-50, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32710249

RESUMEN

INTRODUCTION: Studies of acute hypersensitivity reactions in pediatric populations receiving Crotalidae Polyvalent Immune Fab (CPIF) are complicated by small size, wide age ranges, and diverse definitions of such reactions. METHODS: This is a retrospective chart review of patients aged 13 years or younger treated with CPIF for Crotalid envenomation from November 2006 to 2016. The primary outcome was the presence of an acute hypersensitivity reaction to CPIF and was defined as the development of any of the following symptoms within 3 hours of initiation of CPIF infusion: urticaria, wheezing or respiratory distress, angioedema, hypotension, nausea, and/or vomiting. Demographics, CPIF dose to control and total dose, bite location, level of care, and length of stay were also recorded. RESULTS: Thirty-four patients were ultimately treated with CPIF. Ages ranged from 10 months to 13 years. Twenty-one patients (60%) were male, 24 (70.6%) were admitted to the ICU, and the median length of stay was 2 days with a range of 1-11 days. Zero patients developed an acute hypersensitivity reaction to CPIF. CONCLUSION: Acute hypersensitivity reactions to CPIF did not occur in this cohort. Such reactions are rare with the use of CPIF in pediatric patients.


Asunto(s)
Antivenenos/efectos adversos , Venenos de Crotálidos/antagonistas & inhibidores , Crotalinae , Hipersensibilidad a las Drogas/epidemiología , Fragmentos Fab de Inmunoglobulinas/efectos adversos , Mordeduras de Serpientes/tratamiento farmacológico , Adolescente , Factores de Edad , Animales , Niño , Preescolar , Venenos de Crotálidos/inmunología , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/inmunología , Femenino , Humanos , Lactante , Masculino , Prevalencia , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Mordeduras de Serpientes/diagnóstico , Mordeduras de Serpientes/epidemiología , Mordeduras de Serpientes/inmunología , Factores de Tiempo , Resultado del Tratamiento
20.
Clin Toxicol (Phila) ; 59(3): 193-199, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32609546

RESUMEN

INTRODUCTION: In French Guiana, most snakebites are caused by crotalids, with the main signs being tissue damage and bleeding due to venom-induced coagulopathy. Since December 2014 the Western Guiana Hospital (WGH) has used Antivipmyn Tri TM, a Mexican polyvalent antivenom. The aim of the study was to assess its benefit on the correction of snakebite-related coagulopathy. METHODS: This retrospective study included patients hospitalized at the WGH with snakebite and a coagulopathy defined by: a prothrombin rate (PR) lower than 45%, an activated partial thromboplastin time ratio (aPTTr) greater than 2 or a fibrinogen lower than 100 mg.dL-1. The antivenom group included patients receiving Antivipmyn Tri TM from December 2014 to September 2017. The control group included patients admitted between January 2013 and November 2014 (when antivenom was unavailable) or admitted between December 2014 and September 2017 during times of antivenom shortage. We graphically compared the time courses of PR, aPTTr and fibrinogen between groups. Other endpoints were the length of hospital stay and the need for surgery or dialysis. RESULTS: 84 patients were included: 42 in the antivenom group, 42 in the control group. Both groups were similar for age, sex-ratio, proportion of bleedings, necrosis, and severity. Most patients in the antivenom group received 3 vials. There were no significant differences in recovery of PR, aPTTr and fibrinogen through the first 24 h. Fibrinogen declined again in the control group at 30 h and showed a slower rise to normal concentration. There were no significant differences in any secondary endpoint. CONCLUSION: Antivipmyn Tri TM as currently used did not show any benefit in recovery from coagulopathy.


Asunto(s)
Antivenenos/efectos adversos , Venenos de Crotálidos/antagonistas & inhibidores , Crotalinae , Mordeduras de Serpientes/tratamiento farmacológico , Adolescente , Adulto , Animales , Antivenenos/uso terapéutico , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/etiología , Bothrops , Estudios de Casos y Controles , Crotalus , Femenino , Guyana Francesa , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Insuficiencia del Tratamiento , Viperidae , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...